CAPT: A multicenter randomized controlled trial of perioperative versus postoperative camrelizumab plus apatinib for resectable hepatocellular carcinoma

被引：8

作者：

Bai, X. ^{[1
]}

Chen, Y. ^{[1
]}

Zhang, X. ^{[1
]}

Zhang, F. ^{[2
]}

Liang, X. ^{[3
]}

Zhang, C. ^{[4
]}

Wang, X. ^{[5
]}

Lu, B. ^{[6
]}

Yu, S. ^{[7
]}

Liang, T. ^{[1
]}

机构：

[1] Zhejiang Univ, Sch Med, Hepatobiliary & Pancreat Surg, Affiliated Hosp 1, Hangzhou, Peoples R China

[2] Taizhou Hosp Zhejiang Prov, Hepatobiliary Surg, Taizhou, Peoples R China

[3] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China

[4] Zhejiang Prov Peoples Hosp, Hepatobiliary & Pancreat Surg & Minimally Invas S, Hangzhou, Peoples R China

[5] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Hepatobiliary & Pancreat Surg, Canc Hosp, Hangzhou, Peoples R China

[6] Shaoxing Peoples Hosp, Hepatobiliary & Pancreat Surg, Shaoxing, Peoples R China

[7] Jinhua Cent Hosp, Hepatobiliary & Pancreat Surg, Jinhua, Zhejiang, Peoples R China

来源：

关键词：

D O I：

10.1016/j.annonc.2022.07.836

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

712P

引用

页码：S868 / S868

页数：1